Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV

Journal of Medical Virology

Volumn 70, Issue SUPPL. 1, 2003, Pages

  Brisson, M ^a,b,c   Edmunds, W J ^a,b   Gay, N J ^a  

^a Immunisation Division   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Mathematical modeling; Vaccine effectiveness; Vaccine efficacy; Varicella vaccine; VZV; Zoster

Indexed keywords

CHICKENPOX VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHICKENPOX; CHILD; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HEALTH PROGRAM; HERPES ZOSTER; HOSPITAL PATIENT; HUMAN; INFANT; MATHEMATICAL MODEL; MORBIDITY; NEWBORN; TREATMENT PLANNING; UNITED KINGDOM; UNITED STATES; VACCINATION; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AGED; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; ENGLAND; HERPES ZOSTER; HUMANS; INFANT; MIDDLE AGED; MODELS, BIOLOGICAL; MORBIDITY; TIME FACTORS; WALES;

HUMAN HERPESVIRUS 3;

EID: 0037401827     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10317     Document Type: Conference Paper

References (27)

1. Anderson RM, May RM. 1991. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press. 757 p.
2. Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, Chartrand SA, Cho I, Ngai A, White CJ. 1993. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 92:833-837.
3. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. 1996. Costs and benefits of routine varicella vaccination in Geman children. J Infect Dis 174(Suppl 3):S335-S341.
4. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, Coplan P, Sharrar R, Guess H. 1999. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 18:1041-1046.
5. Brisson M, Edmunds WJ. 2002. The cost-effectiveness of varicella zoster virus (VZV) vaccination in Canada. Vaccine 20:1113-1125.
6. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. 2000a. Modelling the impact of immunisation on the epidemiology of varicella zoster virus. Epidemiol Infect 125:651-669.
7. Brisson M, Edmunds WJ, Law B, De Serres G, Gay NJ. 2000b. Analysis of varicella vaccine breakthrough rates: Implications for the effectiveness of immunisation programmes. Vaccine 18:2775-2778.
8. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G. 2001. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 127:305-314.
9. Brisson M, Gay N, Edmunds WJ, Andrews NJ. 2002. Exposure to Varicella Boosts Immunity to Herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20:2500-2507.
10. Clements DA, Zaref JI, Bland CL, Walter EB, Coplan PM. 2001. Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina. Arch Pediatr Adolesc Med 155:455-461.
11. Committee on Infectious Diseases. 1995. Live attenuated varicella vaccine. Pediatrics 95:791-796.
12. Edmunds WJ, Brisson M, Rose JD. 2001. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19:3076-3090.
13. Garnett GP, Grenfell BT. 1992. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes-zoster. Epidemiol Infect 108:513-528.
14. Gershon AA, LaRussa P, Steinberg S, Mervish N, Lo SH, Meier P. 1996. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 173:450-453.
15. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. 1994. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 140:81-104.
16. Health Canada. 1999. Proceedings of the National Varicella Consensus Conference. Can Commun Dis Rep 25(Suppl):1-29.
17. Hope-Simpson RE. 1965. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 58:9-12.
18. Krause P, Klinman DM. 1995. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr 127:518-525.
19. Palmer SR, Caul EO, Donald DE, Kwantes W, Tillet H. 1985. An outbreak of shingles? Lancet 2:1108-1111.
20. Plotkin S. 1994. Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. Science 265:1383-1385.
21. Schuette MC, Hethcote HW. 1999. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 61:1031-1064.
22. Seward JF, Watson BM, Peterson CL, et al., 2002. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 287:606-611.
23. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA. 2000. The postmarketing safety profile of varicella vaccine. Vaccine 19:916-923.
24. Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A. 1975. Development of a live attenuated varicella vaccine. Biken J 18: 25-33.
25. Thomas SL, Wheeler JG, Hall AJ. 2001. Risk factors for herpes zoster in immunocompetent adults. J Epidemiol Comm Health 55(Suppl): A29 (Abstract 108).
26. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. 2001. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344:955-960.
27. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, Krause PR. 2000. Postlicensure safety surveillance for varicella vaccine. JAMA 284:1271-1279.